394 related articles for article (PubMed ID: 37525244)
21. [Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].
Xu XZ; Liu R; Zhao WH; Yang Y; Liu J; Zhang WG; Bai J; He AL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):838-844. PubMed ID: 38049336
[No Abstract] [Full Text] [Related]
22. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
23. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ
J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046
[TBL] [Abstract][Full Text] [Related]
24. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma.
Reyes KR; Liu YC; Huang CY; Banerjee R; Martin T; Wong SW; Wolf JL; Arora S; Shah N; Chari A; Chung A
Blood Adv; 2024 May; 8(9):2207-2216. PubMed ID: 38429087
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H; Hansen DK; Peres LC; Puglianini OC; Freeman C; De Avila G; Sidana S; Shune L; Sborov DW; Davis J; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Simmons G; Ferreri C; Kalariya N; Anderson LD; Afrough A; Dima D; Khouri J; McGuirk J; Locke F; Baz R; Patel KK; Alsina M
Haematologica; 2024 May; 109(5):1514-1524. PubMed ID: 37855036
[TBL] [Abstract][Full Text] [Related]
26. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
27. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
28. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
29. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.
Lee WH; Graham CE; Wiggin HR; Nolan HK; Graham KJ; Korell F; Leick MB; Barselau AL; Emmanuel-Alejandro E; Trailor MA; Gildea JM; Preffer F; Frigault MJ; Maus MV; Gallagher KME
Cytometry B Clin Cytom; 2024 May; 106(3):162-170. PubMed ID: 38418432
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
31. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
32. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
33. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
Kambhampati S; Sheng Y; Huang CY; Bylsma S; Lo M; Kennedy V; Natsuhara K; Martin T; Wolf J; Shah N; Wong SW
Blood Adv; 2022 Apr; 6(7):2045-2054. PubMed ID: 34543400
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
35. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract][Full Text] [Related]
36. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
37. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
40. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H
Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
